The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of atezolizumab, durvalumab, lurbinectedin, and tarlatamab in high-grade extrapulmonary neuroendocrine carcinoma: A multicenter retrospective comparative analysis.
 
Ty Moore
No Relationships to Disclose
 
Courtney Cavalieri
Honoraria - Pharmacy Times Continuing Education
Consulting or Advisory Role - Oncology Reimbursement Management
 
Sabrina Cannon
No Relationships to Disclose
 
Jessica Campaign Mauser
No Relationships to Disclose
 
Emma Jones
Consulting or Advisory Role - Gather-Ed; KelleyCPharmD LLC
 
Amanda Cass
Honoraria - UpToDate
Consulting or Advisory Role - G1 Therapeutics; Takeda
 
Alexander Olinger
No Relationships to Disclose
 
Bryce Bortka
No Relationships to Disclose
 
Allison Schepers
Employment - University of Michigan Health System
Research Funding - Michigan Oncology Quality Consortium (Inst)
Travel, Accommodations, Expenses - Pharmacy Times Continuing Education
 
Jacob Hobbs
Consulting or Advisory Role - AstraZeneca
 
Lauren Blackwell
No Relationships to Disclose
 
Kori Holman
No Relationships to Disclose
 
Sarah Blocker
No Relationships to Disclose
 
Diana Kim
No Relationships to Disclose
 
Chao Huang
Stock and Other Ownership Interests - Vanguard Funds
Honoraria - Ipsen
Consulting or Advisory Role - Biodesix; Ipsen
Speakers' Bureau - Curio Science; Targeted Oncology
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); EpicentRx; Genentech/Roche (Inst); Henlius (Inst); Mirati Therapeutics (Inst); Novocure (Inst); Pfizer (Inst); Regenxbio (Inst); Summit Therapeutics (Inst)
 
Prakash Neupane
Research Funding - Merck Sharp & Dohme
 
Sanjana Mullangi
No Relationships to Disclose
 
Manidhar Lekkala
Stock and Other Ownership Interests - Abbvie; crispr therapeutics; Lilly; NeoGenomics Laboratories; Pfizer; Teva
 
Haoran Li
No Relationships to Disclose
 
Timothy Schieber
No Relationships to Disclose